Thursday, May 23, 2013 Last update: 1:03 PM
Company Tech News as it Breaks
NeuroSigma, Inc.
News articles for NeuroSigma, Inc.:
Thursday, May 2, 2013
- NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive DisorderLOS ANGELES, May 2, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch(TM) eTNS(TM) (external trigeminal nerve stimulation) System from Health Canada. The license covers the use of the Monarch eTNS System for treatment ... read more
Thursday, April 18, 2013
- Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHDLOS ANGELES, April 18, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced that the results of the first-ever pediatric clinical trial of external Trigeminal Nerve stimulation (eTNS(TM)) for the treatment of attention-deficit hyperactivity disorder (ADHD) will be presented at the American Psychiatric ... read more
Monday, February 4, 2013
- NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant EpilepsyLOS ANGELES, Feb. 4, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced it received a Notice of Award, for a Fast Track Small Business Innovation Research (SBIR) grant, from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes ... read more
Wednesday, January 30, 2013
- NeuroSigma Announces Publication of Randomized Controlled Trial of eTNS for Treatment of Drug Resistant Epilepsy in the Leading Journal, Neurology®LOS ANGELES, Jan. 30, 2013 /PRNewswire/ -- NeuroSigma, Inc., a California-based medical device company, today announced the publication of a positive Phase II clinical study for the use of external Trigeminal Nerve Stimulation (eTNS(TM)) for the treatment of drug-resistant epilepsy. The study, led by Christopher ... read more